CD39+ Regulatory T Cells Attenuate Lipopolysaccharide-Induced Acute Lung Injury via Autophagy and the ERK/FOS Pathway

Cen Chen, Xinying Li, Chuling Li, Jiajia Jin, Donghui Wang, Yuan Zhao, Yanli Gu, Meizi Chen, Suhua Zhu, Hongbing Liu, Tangfeng Lv, Fang Zhang, Yong SongFrontiers in Immunology 2021 · DOI

TL;DR

This study reveals that CD39-expressing regulatory T cells (Tregs) play a crucial protective role in acute lung injury (ALI) by suppressing inflammation. The research demonstrates that these CD39+ Tregs can be therapeutically transferred to mitigate ALI and suggests that their reduced frequency in ARDS patients correlates with disease severity, offering a potential new avenue for ARDS treatment.

What Problem Does This Paper Address?

Acute Respiratory Distress Syndrome (ARDS) is a severe, life-threatening condition characterized by overwhelming lung inflammation and a high mortality rate, with limited effective treatments. Regulatory T cells (Tregs) are known to be critical for maintaining immune balance and suppressing excessive inflammation. CD39 is a cell surface marker often associated with the functional capacity of Tregs. However, the specific role of CD39+ Tregs in ARDS and the underlying mechanisms by which their function might be regulated during this condition were not well understood. This paper aims to elucidate the protective role of CD39+ Tregs in ALI, a model for ARDS, and to investigate their frequency and potential therapeutic application in ARDS patients.

Methods

The researchers employed a multi-pronged approach:

  • Animal Models: They utilized CD39 knockout (KO) mice and wild-type (WT) mice to study the role of CD39 in LPS-induced ALI.
  • In Vitro Studies: They isolated and activated Tregs from mice and co-cultured them with macrophages to assess the anti-inflammatory effects of CD39+ Tregs and the impact of adenosine.
  • Adoptive Transfer: CD39+ Tregs were transferred into mice with ALI to evaluate their therapeutic potential.
  • Molecular Mechanisms:
    • Immunofluorescence: Used to visualize CD39 and Foxp3 expression in lung tissue.
  • Flow Cytometry: Employed to quantify the frequency of Tregs and CD39 expression on these cells in blood, spleen, and bronchoalveolar lavage fluid (BALF).
  • ELISA and qRT-PCR: Used to measure cytokine levels (IL-6, IL-1β, TNF-α) in BALF and plasma, and mRNA expression.
  • Western Blotting: Investigated the activation of signaling pathways, specifically ERK1/2 and FOS.
  • Autophagy Assays: Utilized GFP-mRFP-LC3 lentivirus and siRNA knockdown of autophagy genes (BECN1, ATG5) to study the role of autophagy in CD39 regulation.
  • Chromatin Immunoprecipitation (ChIP) and Luciferase Reporter Assays: Explored the transcriptional regulation of CD39 by FOS.
  • Human Patient Samples: Peripheral blood mononuclear cells (PBMCs) from ARDS patients and healthy controls were analyzed for CD39+ Treg frequency.

Datasets

The study primarily used data generated from experiments involving:

  • Mouse Models: CD39 knockout mice and wild-type C57BL/6J mice.
  • Human Samples: PBMCs from 20 ARDS patients and 13 healthy donors.

No new public benchmarks were introduced.

Key Insights and Ideas

  • CD39+ Tregs are protective in ALI: The absence of CD39 exacerbates ALI, while the adoptive transfer of CD39+ Tregs ameliorates the condition. This highlights CD39 as a key functional marker for protective Tregs in lung injury.
  • Autophagy downregulates CD39 on Tregs during inflammation: LPS-induced inflammation triggers autophagy in Tregs, which in turn suppresses CD39 expression. This suggests a mechanism by which inflammation can impair Treg function.
  • CD39 has a positive feedback loop via ERK/FOS: CD39 can self-upregulate its expression by activating the ERK1/2-FOS pathway in Tregs. This creates a feedback loop that likely enhances Treg's anti-inflammatory capacity and resilience.
  • Reduced CD39+ Tregs in ARDS patients: The frequency of CD39+ Tregs is significantly lower in ARDS patients compared to healthy individuals, and this reduction correlates with disease severity. This finding strongly suggests a clinical relevance for CD39+ Tregs in ARDS.

Key Results

  • Survival: CD39-/- mice showed significantly reduced survival following LPS-induced ALI compared to WT mice.
  • Lung Injury: CD39 deficiency led to increased lung injury scores, neutrophil infiltration, and pro-inflammatory cytokine levels (IL-6, IL-1β, TNF-α) in BALF and plasma.
  • Treg Frequency: LPS stimulation in WT mice caused a transient decrease in CD39 expression on Tregs in peripheral blood and spleen.
  • In Vitro Efficacy: CD39+ Tregs, when co-cultured with macrophages, significantly reduced LPS-induced IL-6, IL-1β, and TNF-α expression. Adenosine treatment further enhanced this suppressive effect.
  • In Vivo Efficacy: Adoptive transfer of CD39+ Tregs attenuated ALI, reducing lung injury, inflammatory cell infiltration, and pro-inflammatory cytokine levels.
  • Mechanism: Autophagy inhibition (siBECN1 or siATG5) reversed LPS-induced CD39 downregulation. Activation of ERK1/2 and FOS was increased in CD39+ Tregs, and inhibiting ERK1/2 reduced CD39 expression. FOS was shown to bind to a specific region of the CD39 promoter.
  • Human Data: ARDS patients exhibited a significantly lower percentage of CD39+ Tregs in their PBMCs, with a progressive decrease observed from mild to severe ARDS.

Limitations and Future Work

  • Autophagy and ERK/FOS Interplay: While the study shows that autophagy downregulates CD39 and ERK/FOS upregulates it, the precise interplay and how these pathways are coordinated during inflammation require further investigation.
  • Clinical Translation: Although promising, the study is preclinical. Further research is needed to optimize the adoptive transfer of CD39+ Tregs for clinical application in ARDS.
  • Broader Mechanisms: The study focuses on autophagy and ERK/FOS. Other regulatory mechanisms influencing CD39 expression on Tregs in the context of ARDS might exist.
  • Long-term Effects: The long-term effects and potential side effects of CD39+ Treg-based therapies are not yet known.

The authors suggest that CD39+ Treg-based therapeutics could be a novel approach for the early diagnosis, prevention, and precise treatment of ARDS.

Summary updated

Abstract

Acute respiratory distress syndrome (ARDS) is characterized by an uncontrollable cytokine storm, which is associated with high mortality due to lack of effective treatment. Regulatory T cells (Tregs) play an indispensable role in maintaining immune homeostasis and CD39 is considered as a functional cell marker of Tregs. In this study, we aimed to evaluate the effect of CD39<sup>+</sup> Tregs on acute lung injury (ALI) and investigate the frequency of CD39<sup>+</sup> Tregs in ARDS patients. We found that after lipopolysaccharide (LPS) treatment, CD39<sup>-/-</sup> mice exhibited more severe inflammation and wild type (WT) mice exhibited a decreased frequency of CD39<sup>+</sup> Tregs in the peripheral blood. Furthermore, CD39<sup>+</sup> Tregs had a protective effect on LPS-induced inflammation <i>in vitro</i> and the adoptive transfer of CD39<sup>+</sup> Tregs had a therapeutic effect on ALI <i>in vivo</i>. We further sought to explore the mechanisms that affect CD39 expression on Tregs. LPS-induced inflammation in the lung impaired the immunosuppressive effect of Tregs <i>via</i> the autophagy-mediated downregulation of CD39. In addition, CD39 induced the expression of itself in Tregs <i>via</i> activating the ERK1/2-FOS pathway. Consistent with this finding, the frequency of CD39<sup>+</sup> Tregs was also decreased in the peripheral blood of ARDS patients and was positively correlated with disease severity. Our results suggested that the adoptive transfer of CD39<sup>+</sup> Tregs may provide a novel method for the clinical prevention and treatment of ARDS.
BibTeX
@inproceedings{chen2021cd,
  author = {Cen Chen and Xinying Li and Chuling Li and Jiajia Jin and Donghui Wang and Yuan Zhao and Yanli Gu and Meizi Chen and Suhua Zhu and Hongbing Liu and Tangfeng Lv and Fang Zhang and Yong Song},
  title = {{CD39+ Regulatory T Cells Attenuate Lipopolysaccharide-Induced Acute Lung Injury via Autophagy and the ERK/FOS Pathway}},
  booktitle = {Frontiers in Immunology},
  year = {2021},
  doi = {10.3389/fimmu.2020.602605},
}
Figure